Anti-Cancer Drug Design

Preface
pp. 311-313(3)
Author: Crooke, ST

Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics
pp. 315-326(12)
Authors: McGraw, K; McKay, R; Miraglia, L; Boggs, RT; Pribble, JP; Muller, M; Geiger, T; Fabbro, D; Dean, NM

First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies
pp. 327-339(13)
Author: Monia, BP

Developing oligonucleotide therapeutics for human leukemia
pp. 341-358(18)
Author: Gewirtz, AM

In vitro and in vivo activity of antisense inhibitors of ras:potential for clinical development
pp. 359-371(13)
Author: Cowsert, LM

Targeting c-myc in leukemia
pp. 373-381(9)
Authors: Calabretta, B; Skorski, T

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
pp. 383-393(11)
Authors: Geary, RS; Leeds, JM; Henry, SP; Monteith, DK; Levin, AA

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides
pp. 395-408(14)
Authors: Henry, SP; Monteith, DK; Levin, AA

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase
pp. 409-420(12)
Authors: Henry, SP; Monteith, DK; Bennett, F; Levin, AA

Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents
pp. 421-432(12)
Authors: Henry, SP; Monteith, DK; Bennett, CF; Levin, AA; Howard, RB; Flournoy, S; Crooke, ST

Recent developments in triple-helix regulation of gene expression
pp. 433-442(10)
Author: Neidle, S